PharmiWeb.com - Global Pharma News & Resources
21-Jun-2019

Hemophilia Market size to Garner more than US$ 17 Billion by 2026

Global Hemophilia Market Size is expected to reach USD 17 Billion by 2026 and growing CAGR around 5.3 % during the forecast period.

The increasing initiatives for creating awareness about hemophilia drugs from the government as well as non-government organizations at an international level is one of the prime factors boosting the market growth. Also, the increase in delivering a prophylactic treatment is likely to fuel the demand for hemophilia.

The global hemophilia market is segmented into type, treatment, therapy, and region. On the basis of type, the global hemophilia market is segmented into Hemophilia A, Hemophilia B, Hemophilia C. The global Hemophilia market is also segmented by treatment. This segmentation includes On-demand and Prophylaxis. The hemophilia market is also bifurcated on the basis of therapy which includes Replacement Therapy, Gene Therapy. On the basis of the region the global agricultural fumigants market is bifurcated into Europe, Latin America, North America, Middle East amp; Africa, and the Asia Pacific.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1239

Hemophilia drugs are coming out to be one of the crucial medicinal product to limit the loss of blood as there is no precise treatment available to treat this disorder. Among the types of disorders, type A is predicted to be four times more prevalent than type B also it is the most commonly occurring type. The types of hemophilia are characterized on the basis of the coagulation factor deficiency present in particular patient. The growth of type A segment is expected to be moderate over the forecast period as for the treatment of Type A multiple drugs are available from the pharmaceutical industry. The company named Baxalta, which is one of the leading Type A drugs supplier for Hemophilia in Japan, China, South Africa, U.S., Germany, and the U.K. The company provides drugs named as Advate and Recombinate. The government limitations for the distribution of these drugs in some countries are although limiting the growth of the market.

According to the National Hemophilia Organization, the exact numbers of worldwide incidence of hemophilia are not well known, but it is estimated at more than 400,000 people. The organization also states that approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment. The manufacturers of treatment drugs for this disorder are facing a significant challenge while coming up with suitable treatment for hemophilia as there is no exact drug is available. The regulatory bodies are facing increasing pressure to create a therapy for hemophilia disorder and due to such factors, the research and development projects are increasing rapidly.

The Asia Pacific region is expected to be the fastest developing region segment over the forecast period. The increasing initiative taken by the government to promote the usage of hemophilia drugs is foreseen to accelerate the demand for hemophilia over the forecast period. Also, the application of hemophilia in the Key therapies including replacement therapy, Immune Tolerance Induction therapy, and gene therapy is boosting the growth in this region. Europe is one of the huge consumers of hemophilia as the pharmaceutical advancements in this region. In addition, constant research and development activities going on in the developed countries present in this region such as U.K., Germany, and others is boosting the awareness and consumption of hemophilia and hence boosting the market growth. Considering the regions, the North America region is holding a lion's share in the global hemophilia market in terms of revenue generation from the sale of hemophilia. The North America region is holding the highest market share and expected to continue a similar trend by the end of the forecast period. The factors such as a rise in awareness about the hemophilia disorder and need to have a cure for this are propelling the market growth in this region.

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1239

Some of the leading players are providing hemophilia drugs to global locations. These players are focused on delivering government complaint products to patients. The players catering to the global hemophilia market includes Baxalta, CSL Behring, Pfizer, Inc., Bayer Healthcare, BioMarin Pharmaceutical, Inc., Biogen, Chugai Pharmaceutical Co., Novo Nordisk, Shire Plc., and others.

These players are constantly upgrading their strategies to boost revenue generation and market share. For example, in May 2017, Pfizer Inc. which is a one of the leading provider of hemophilia signed a collaboration agreement with Sangamo Therapeutics, Inc. it also includes a global license for developing and commercialize gene therapy programs intended to be utilized for Hemophilia A.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Hemophilia
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Hemophilia Market By Type
1.2.2.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Hemophilia Market Revenue Share By Type in 2017
1.2.2.3. Hemophilia A
1.2.2.4. Hemophilia B
1.2.2.5. Hemophilia C
1.2.2.6. Others
1.2.3. Hemophilia Market By Treatment
1.2.3.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Treatment (2015-2026)
1.2.3.2. On-demand
1.2.3.3. Prophylaxis
1.2.3.4. Others
1.2.4. Hemophilia Market By Therapy
1.2.4.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Therapy (2015-2026)
1.2.4.2. Replacement Therapy
1.2.4.3. Gene Therapy
1.2.4.4. Others
1.2.5. Hemophilia Market by Geography
1.2.5.1. Global Hemophilia Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Hemophilia Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Hemophilia Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Hemophilia Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Hemophilia Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Hemophilia Major Manufacturers in 2017

CHAPTER 4. HEMOPHILIA MARKET BY TYPE

4.1. Global Hemophilia Revenue By Type
4.2. Hemophilia A
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Hemophilia B
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Hemophilia C
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Other
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. HEMOPHILIA MARKET BY TREATMENT

5.1. Global Hemophilia Revenue By Treatment
5.2. On-demand
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Prophylaxis
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. HEMOPHILIA MARKET BY THERAPY

6.1. Global Hemophilia Revenue By Therapy
6.2. Replacement Therapy
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Gene Therapy
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Others
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA HEMOPHILIA MARKET BY COUNTRY

7.1. North America Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Hemophilia Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. U.S.
7.3.1. U.S. Hemophilia Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE HEMOPHILIA MARKET BY COUNTRY

8.1. Europe Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Hemophilia Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC HEMOPHILIA MARKET BY COUNTRY

9.1. Asia-Pacific Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Hemophilia Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA HEMOPHILIA MARKET BY COUNTRY

10.1. Latin America Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Hemophilia Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST HEMOPHILIA MARKET BY COUNTRY

11.1. Middle East Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Hemophilia Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA HEMOPHILIA MARKET BY COUNTRY

12.1. Africa Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Hemophilia Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Baxalta
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. CSL Behring
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Pfizer, Inc.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Bayer Healthcare
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. BioMarin Pharmaceutical, Inc.
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Biogen
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Chugai Pharmaceutical Co.
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Novo Nordisk
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Shire Plc.
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Others
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/1239

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 21-Jun-2019